Ignite Creation Date:
2025-12-25 @ 12:00 AM
Ignite Modification Date:
2026-03-07 @ 11:47 PM
Study NCT ID:
NCT00553358
Status:
COMPLETED
Last Update Posted:
2021-09-21
First Post:
2007-11-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neoplasms, Breast | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lapatinib | View |
| None | ErbB2+ | View |
| None | Early Breast Cancer | View |
| None | Neoadjuvant | View |
| None | breast carcinoma | View |
| None | breast cancer | View |
| None | breast lump | View |
| None | HER2 positive metastatic breast cancer | View |
| None | breast cancer positive for human epidermal growth factor receptor 2 … | View |
| None | breast cancer progression | View |
| None | estrogen-receptor (ER) positive(+) breast cancer | View |
| None | Paget's disease | View |